Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).

Abstract

BACKGROUND:

Mineralocorticoid receptor antagonists improve outcomes in patients with systolic heart failure but may induce worsening of renal function (WRF) and hyperkalemia (HK). We assessed the risk factors for mineralocorticoid receptor antagonist-related WRF and for HK, as well as the association between HK and WRF with clinical outcomes in the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).

METHODS AND RESULTS:

Serial changes in estimated glomerular filtration rate and in serum potassium were available in 2737 patients during a median 21-month follow-up. HK variably defined as serum K>4.5, 5, or 5.5 mmol/L occurred in 74.7%, 32.5%, and 8.9% patients enrolled in EMPHASIS-HF, respectively. WRF defined as a decrease in estimated glomerular filtration rate>20% or >30% from baseline occurred in 27% and 14% of patients, respectively. Patients assigned eplerenone displayed modest and early but significant and persistent (1) rise in serum potassium and (2) reduction in estimated glomerular filtration rate when compared with those assigned placebo. In multivariate analyses, eplerenone was associated with a higher incidence of WRF and HK, which were interrelated and also associated with baseline patient characteristics (eg, age≥75 years, hypertension, diabetes mellitus, nonwhite race, ejection fraction<30%, and treatment with an antiarrythmics drug or loop diuretic). Eplerenone retained its survival benefits without any significant interaction with the association between HK>5.5 mmol/L only and WRF and worse outcomes.

CONCLUSIONS:

In patients with heart failure receiving optimal therapy, WRF and HK were more frequent when eplerenone was added, but their occurrence did not eliminate the survival benefit of eplerenone.

CLINICAL TRIAL REGISTRATION:

URL: http://www.clinicaltrials.gov. Unique identifier: NCT00232180.

• Authors: Patrick Rossignol, Daniela Dobre, John J V McMurray, Karl Swedberg, Henry Krum, Dirk J van Veldhuisen, Harry Shi, Michael Messig, John Vincent, Nicolas Girerd, George Bakris, Bertram Pitt, Faiez Zannad
• Journal: Circulation. Heart failure (Circ Heart Fail) Vol. 7 Issue 1 Pg. 51-8 (Jan 2014) ISSN: 1941-3297 [Electronic] United States
• PMID: 24297687 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Mineralocorticoid Receptor Antagonists
• Spironolactone
• Eplerenone
• Potassium

Topics

• Acute Kidney Injury (epidemiology, physiopathology)
• Aged
• Aged, 80 and over
• Eplerenone
• Female
• Follow-Up Studies
• Glomerular Filtration Rate (physiology)
• Heart Failure (diagnosis, drug therapy, mortality)
• Hospitalization
• Humans
• Hyperkalemia (blood, epidemiology)
• Incidence
• Longitudinal Studies
• Male
• Mineralocorticoid Receptor Antagonists (adverse effects, therapeutic use)
• Multivariate Analysis
• Potassium (blood)
• Prognosis
• Risk Factors
• Spironolactone (adverse effects, analogs & derivatives, therapeutic use)
• Survival Rate